Compare Stocks: FATE, GLUE, KURA, and SANA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.31 -0.9%	$2.61	$0.94 ▼ $3.23	$276.79M	2.54	1.25 million shs	742,390 shs
GLUE Monte Rosa Therapeutics	$14.07 -1.7%	$18.05	$4.80 ▼ $25.77	$1.20B	1.5	995,057 shs	1.17 million shs
KURA Kura Oncology	$11.39 -1.6%	$11.23	$7.36 ▼ $13.90	$1.01B	0.44	2.25 million shs	2.12 million shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$937M	2.12	2.92 million shs	3.28 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	-6.85%	-8.33%	+12.14%	+131.00%
GLUE Monte Rosa Therapeutics	0.00%	+1.66%	-11.17%	-22.86%	+193.13%
KURA Kura Oncology	0.00%	-14.04%	+12.88%	+25.86%	+39.41%
SANA Sana Biotechnology	0.00%	-18.70%	-14.71%	+16.79%	+7.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.31 -0.9%	$2.61	$0.94 ▼ $3.23	$276.79M	2.54	1.25 million shs	742,390 shs
GLUE Monte Rosa Therapeutics	$14.07 -1.7%	$18.05	$4.80 ▼ $25.77	$1.20B	1.5	995,057 shs	1.17 million shs
KURA Kura Oncology	$11.39 -1.6%	$11.23	$7.36 ▼ $13.90	$1.01B	0.44	2.25 million shs	2.12 million shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$937M	2.12	2.92 million shs	3.28 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	-6.85%	-8.33%	+12.14%	+131.00%
GLUE Monte Rosa Therapeutics	0.00%	+1.66%	-11.17%	-22.86%	+193.13%
KURA Kura Oncology	0.00%	-14.04%	+12.88%	+25.86%	+39.41%
SANA Sana Biotechnology	0.00%	-18.70%	-14.71%	+16.79%	+7.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.38	Hold	$5.90	155.41% Upside
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	102.56% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	123.00% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	198.19% Upside

Current Analyst Ratings Breakdown

Latest FATE, GLUE, KURA, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.65M	41.62	N/A	N/A	$1.80 per share	1.28
GLUE Monte Rosa Therapeutics	$123.67M	9.71	N/A	N/A	$3.58 per share	3.93
KURA Kura Oncology	$67.48M	15.02	N/A	N/A	$2.00 per share	5.70
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest FATE, GLUE, KURA, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	4.85	4.85
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
KURA Kura Oncology	0.12	4.73	4.71
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
GLUE Monte Rosa Therapeutics	79.96%
KURA Kura Oncology	N/A
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
GLUE Monte Rosa Therapeutics	6.40%
KURA Kura Oncology	7.60%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
GLUE Monte Rosa Therapeutics	173	85.31 million	79.85 million	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable

FATE, GLUE, KURA, and SANA Headlines

Recent News About These Companies

Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段

September 10 at 9:07 PM | cn.investing.com

Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法

September 10 at 9:07 PM | cn.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10 at 5:00 PM | seekingalpha.com

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10 at 4:06 PM | seekingalpha.com

Bank of New York Mellon Corp Invests $1.67 Million in Sana Biotechnology, Inc. $SANA

September 9, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.9% - What's Next?

September 8, 2026 | marketbeat.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

September 7, 2026 | prnewswire.com

Corient Private Wealth LP Invests $2.19 Million in Sana Biotechnology, Inc. $SANA

September 3, 2026 | marketbeat.com

Sana Biotechnology to Present at September 2026 Investor Conferences

September 1, 2026 | globenewswire.com

16,675,173 Shares in Sana Biotechnology, Inc. $SANA Acquired by BlackRock Inc.

September 1, 2026 | marketbeat.com

Canada Pension Plan Investment Board Purchases Shares of 10,218,400 Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Stake in Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

As U.S.-China biotech race heats up, Seattle makes its case to D.C.

August 27, 2026 | msn.com

As US.-China biotech race heats up, Seattle makes its case to DC

August 27, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7% After Analyst Upgrade

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Bank of America Corp DE Has $8.49 Million Stock Position in Sana Biotechnology, Inc. $SANA

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention

August 21, 2026 | kalkinemedia.comK

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts

August 21, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?

August 20, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% - Still a Buy?

August 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, GLUE, KURA, and SANA Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.31 -0.02 (-0.86%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.39 +0.08 (+3.59%)

As of 09/11/2026 07:59 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$14.07 -0.25 (-1.75%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$14.08 +0.00 (+0.04%)

As of 09/11/2026 07:39 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Kura Oncology NASDAQ:KURA

$11.39 -0.18 (-1.56%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.45 +0.06 (+0.53%)

As of 09/11/2026 07:40 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Sana Biotechnology NASDAQ:SANA

$3.13 +0.04 (+1.29%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.15 +0.02 (+0.64%)

As of 09/11/2026 07:56 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, GLUE, KURA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, GLUE, KURA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, GLUE, KURA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, GLUE, KURA, and SANA Company Descriptions

Fate Therapeutics NASDAQ:FATE

Monte Rosa Therapeutics NASDAQ:GLUE

Kura Oncology NASDAQ:KURA

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, GLUE, KURA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, GLUE, KURA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, GLUE, KURA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, GLUE, KURA, and SANA Company Descriptions

Fate Therapeutics NASDAQ:FATE

Monte Rosa Therapeutics NASDAQ:GLUE

Kura Oncology NASDAQ:KURA

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools